Overview
The purpose of this study is to investigate the use of ultra-low, anti-inflammatory doses of radiation therapy (RT) for the treatment of Parkinson's Disease (PD). In this study, the TrueBeam LINAC utilizes a linear accelerator (LINAC) for the delivery of radiation therapy. Dynamic conformal arc (DCA) therapy will be used to deliver a total of five (5) once-a-day radiation treatments (RT) using DaT-SPECT (Dopamine Transporter-Single-Photon Emission Computed Tomography) and MRI imaging to guide radiation treatment planning.
Eligibility
Inclusion Criteria
- Age ≥ 45 and ≤ 70 years
- Diagnosis of Parkinson's disease by a Movement Disorder Neurologist
- Confirmation of unilateral Parkinson's disease by Dopamine Transporter (DaT) scan
- A score of 2 or less on the modified Hoehn and Yahr scale
- ECOG Performance Status (PS) ≤ 2 (Appendix I).
- No known genetic causes or predisposition to Parkinson's disease or related diseases.
- Ability to complete questionnaires, neurological exam, and follow-up imaging independently or with assistance
- Ability to provide written informed consent
- Willing to provide mandatory blood samples for correlative research purposes
- Willing to return to enrolling institution for follow-up
Exclusion Criteria
- Concomitant dementia diagnosis or concerns of other memory disorder
- Parkinson's Disease medication changes within the last 3 months
- Receipt of radiation therapy for Parkinson's Disease outside Mayo Clinic, Rochester